Recurrent IgA nephropathy after renal transplantation: not always a benign prognosis
-
摘要:
目的 探讨肾移植后IgA肾病(IgAN)复发的临床病理特征及其预后。 方法 选取1996年1月至2009年4月期间在南京军区南京总医院国家肾脏疾病临床医学研究中心接受肾移植的148例IgAN终末期肾衰竭受者为研究对象。根据肾移植后有否IgAN复发分为IgAN复发组(46例)和非IgAN复发组(102例)。比较IgAN复发组和非IgAN复发组受者肾移植术后0、1、2、3、5年尿沉渣红细胞(U-RBC)计数、24 h尿蛋白定量、肾功能[血清肌酐(Scr)、肾小球滤过率(GFR)]; 比较两组受者术后移植肾病理组织学损伤的发生率和移植肾存活率。 结果 IgAN复发组肾移植术后U-RBC计数、24 h尿蛋白定量逐渐增加, 肾功能逐渐变差。与非IgAN复发组比较, IgAN复发组术后2、3、5年的U-RBC计数明显增加, 术后5年的肾功能明显较差(均为P < 0.01~0.001)。移植肾病理学结果示, 与非IgAN复发组比较, IgAN复发组的细胞性新月体形成、肾小球粘连、系膜细胞增生、系膜基质增多、球性硬化、肾小球节段硬化、球性废弃和肾间质纤维化等的发生率均明显升高(均为P < 0.001)。IgAN复发组和非IgAN复发组的慢性移植肾损伤指数分别为7.7±2.3和4.6±1.4(P < 0.01)。与非IgAN复发组比较, IgAN复发组的慢性排斥反应发生率、移植肾肾小球病(不包括IgAN)和C4 d沉积阳性发生率均较高(P < 0.01~0.001)。IgAN复发组和非IgAN复发组肾移植术后1年移植肾存活率分别为93.8%和95.6%(P>0.05), 术后3年分别为86.7%和88.3%(P>0.05), 术后5年分别为51.4%和83.8%(P < 0.001)。IgAN复发组中10例(22%)患者和非IgAN复发组中9例(9%)患者发生移植肾丧失。 结论 肾移植术后IgA肾病复发以无症状性镜下血尿、蛋白尿和肾功能呈进行性下降为特征, 会降低移植肾长期存活率, 提示预后不良。 Abstract:Objective To discuss the clinicopathological characteristics and prognosis of the recurrence of IgA nephropathy (IgAN) after renal transplantation. Methods A total of 148 patients, pathologically diagnosed with IgAN which progressed into end-stage renal failure, undergoing renal transplantation in National Clinical Medical Research Center of Kidney Diseases, Nanjing General Hospital of Nanjing Military Command from January 1996 to April 2009, were included in this study.According to whether IgAN recurred, all patients were assigned into recurrence (n=46) and non-recurrence groups (n=102). Urinary red blood cell (U-RBC) count, 24 h urinary protein level, renal function including serum creatinine (Scr) and glomerular filtration rate (GFR) at 0, 1, 2, 3 and 5 years after renal transplantation were statistically compared between two groups. The incidence of histopathological renal injury and survival rate of transplant kidneys was compared between two groups. Results In recurrence group, U-RBC count and 24 h urinary protein level were gradually elevated and renal function steadily declined. Compared with non-recurrence group, U-RBC count at 2-, 3-and 5-year after renal transplantation significantly increased, and renal function was significantly aggravated at postoperative 5 years (all in P < 0.01-0.001) in recurrence group. Renal pathological findings revealed that compared with non-recurrence group, the incidence of cellular crescent formation, glomerulus adhesion, mesangial cell proliferation, increased mesentery matrix, glomerulosclerosis, segmental glomerulosclerosis, glomerular dysfunction and tubulointerstitial fibrosis was significantly higher in recurrence group (all in P < 0.001). After renal transplantation, chronic kidney injury index in recurrence group was 7.7±2.3, which was significantly higher than 4.6±1.4 in non-recurrence group (P < 0.01). Compared with non-recurrence group, the incidence of chronic rejection, glomerulopathy of transplant kidney(without IgAN) and positive C4d deposition was significantly higher in recurrence group (P < 0.01-0.001). At 1-and 3-year after renal transplantation, survival rates of transplant kidney did not significantly differ between recurrence and non-recurrence groups(93.8% vs. 86.7%, 95.6% vs. 88.3%, both in P>0.05). However, the survival rate at 5 years after transplantation was 51.4% in recurrence group, significantly lower compared with 83.8% in non-recurrence group (P < 0.001). In recurrence group, 10 patients (22%) presented with renal failure after renal transplantation, and 9 patients(9%) in non-recurrence group. Conclusions After renal transplantation, the recurrence of IgAN characterized by asymptomatic microscopic hematuria, albuminuria and progressive aggravation of renal function reduce long-term survival rate of renal graft and indicate poor prognosis. -
Key words:
- Renal transplantation /
- Biopsy /
- IgA nephropathy /
- Urinary sediment /
- Red blood cell /
- Albuminuria /
- Recurrence /
- Prognosis
-
图 1 两组受者肾移植术后尿沉渣红细胞计数和尿蛋白定量的比较
注：与非IgAN复发组比较，aP < 0.001
Figure 1. The comparison of urinary sediment red blood cell count and urine protein quantitation of recipients between two groups after renal transplantation
图 2 两组受者肾移植术后肾功能的比较
注：与非IgAN复发组比较，aP < 0.001；Scr单位换算为1 mg/dl=88.4 μmol/L
Figure 2. The comparison of renal function of recipients between two groups after renal transplantation
-
[1] 乐伟波, 梁少珊, 邓康平, 等.1 126例中国汉族成人IgA肾病患者的长期预后及危险因素分析[J].肾脏病与透析肾移植杂志, 2011, 20(2):101-108.Le WB, Liang SS, Deng KP, et al. Long-term renal survival and related risk factors of patients with IgA nephropathy: results from a cohort of 1 126 cases in a Chinese adult population[J]. Chin J Nephrol Dial Transplant, 2011, 20(2):101-108. [2] 沈霞红, 梁少姗, 乐伟波, 等. IgA肾病患者肾组织病变的变化与治疗及预后的关系[J].肾脏病与透析肾移植杂志, 2013, 22(5):401-408. http://www.cnki.com.cn/Article/CJFDTOTAL-SZBY201305001.htmShen XH, Liang SS, Le WB, et al. Clinicopathologic features and treatment response in IgA nephropathy[J]. Chin J Nephrol Dial Transplant, 2013, 22(5):401-408. http://www.cnki.com.cn/Article/CJFDTOTAL-SZBY201305001.htm [3] Working Group of the International IgA nephropathy Network and the Renal Pathology Society, Coppo R, Troyanov S, et al. The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults[J]. Kidney Int, 2010, 77(10):921-927. doi: 10.1038/ki.2010.43 [4] Han SS, Huh W, Park SK, et al. Impact of recurrent disease and chronic allograft nephropathy on the long-term allograft outcome in patients with IgA nephropathy[J]. Transpl Int, 2010, 23(2):169-175. doi: 10.1111/tri.2009.23.issue-2 [5] Bulut IK, Mir S, Sozeri B, et al. Outcome results in children with IgA nephropathy: a single center experience[J]. Int J Nephrol Renovasc Dis, 2012, 5:23-28. http://core.ac.uk/display/27365227 [6] 姜飞, 俞东容, 蔡丽丽, 等. IgA肾病预后危险因素研究进展[J].中国中西医结合肾病杂志, 2014, 15(11):1024-1026. http://www.cnki.com.cn/Article/CJFDTOTAL-JXSB201411041.htmJiang F, Yu DR, Cai LL, et al. Research progress on the prognostic risk factors of IgA nephropathy [J]. Chin J Integr Tradit West Nephrol, 2014, 15(11):1024-1026. http://www.cnki.com.cn/Article/CJFDTOTAL-JXSB201411041.htm [7] Han SS, Huh W, Park SK, et al. Impact of recurrent disease and chronic allograft nephropathy on the long-term allograft outcome in patients with IgA nephropathy[J]. Transpl Int, 2010, 23(2):169-175. doi: 10.1111/tri.2009.23.issue-2 [8] 鲁琳.肾移植后IgA肾病复发的研究进展[J].国际泌尿系统杂志, 2010, 30(5):681-684. http://www.cnki.com.cn/Article/CJFDTOTAL-JXSB200704024.htmLu L. The development of the research of recurrent IgA nephropathy after renal transplantation[J]. Int J Urol Nephrol, 2010, 30(5):681-684. http://www.cnki.com.cn/Article/CJFDTOTAL-JXSB200704024.htm [9] 方明, 林洪丽, 谢华, 等.促纤溶治疗对IgA肾病患者肾脏保护的回顾性队列研究[J].实用医学杂志, 2014, 30(9):1405-1407. http://www.cnki.com.cn/Article/CJFDTOTAL-SYYZ201409019.htmFang M, Lin HL, Xie H, et al. Fibrinolytic therapy on renal protection in IgA nephropathy patients:a retrospective cohort study[J]. J Pract Med, 2014, 30(9):1405-1407. http://www.cnki.com.cn/Article/CJFDTOTAL-SYYZ201409019.htm [10] 郭君其, 凌志杰, 王科, 等.移植肾肾病复发和新发患者的临床病理分析[J].临床泌尿外科杂志, 2011, 26(1):28-31. http://www.cnki.com.cn/Article/CJFDTOTAL-LCMW201101014.htmGuo JQ, Ling ZJ, Wang K, et al. The analyses of patients with recurrent glomerulonephritis and de novo glomerulonephritis posttransplantation[J]. J Clin Urol, 2011, 26(1):28-31. http://www.cnki.com.cn/Article/CJFDTOTAL-LCMW201101014.htm [11] Floege J, Gröne HJ. Recurrent IgA nephropathy in the renal allograft: not a benign condition[J]. Nephrol Dial Transplant, 2013, 28(5):1070-1073. doi: 10.1093/ndt/gft077 [12] Matsukura H, Igarashi N, Kazama T, et al. Concurrent occurrence of juvenile reactive arthritis and IgA nephropathy[J].Clin Nephrol, 2014, 81(5):379-380. doi: 10.5414/CN108200 [13] 周姗姗, 李剑文, 梁鸣, 等.548例肾脏疾病患者临床及病理分析[J].热带医学杂志, 2014, 14(6):767-770, 776. http://www.cnki.com.cn/Article/CJFDTOTAL-RDYZ201406026.htmZhou SS, Li JW, Liang M, et al. Clinical and pathological analysis of 548 cases with chronic kidney disease[J]. J Trop Med, 2014, 14(6):767-770, 776. http://www.cnki.com.cn/Article/CJFDTOTAL-RDYZ201406026.htm [14] Buron F, Hadj-Aissa A, Dubourg L, et al. Estimating glomerular filtration rate in kidney transplant recipients: performance over time of four creatinine-based formulas[J]. Transplantation, 2011, 92(9):1005-1011. http://www.medscape.com/medline/abstract/22031008 [15] Solez K, Colvin RB, Racusen LC, et al. Banff'05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy('CAN')[J]. Am J Transplant, 2007, 7(3):518-526. doi: 10.1111/ajt.2007.7.issue-3 [16] Wang Y, Ichimaru N, Kyo M, et al. Beneficial effects of tonsillectomy for mesangial immunoglobulin A (IgA) deposition and clinical outcome in five kidney transplant patients with recurrent IgA nephropathy: case report[J]. Transplant Proc, 2014, 46(2):607-609. doi: 10.1016/j.transproceed.2013.11.066 [17] Von Visger JR, Gunay Y, Andreoni KA, et al. The risk of recurrent IgA nephropathy in a steroid-free protocol and other modifying immunosuppression[J]. Clin Transplant, 2014, 28(8):845-854. doi: 10.1111/ctr.2014.28.issue-8 [18] Chhabra D, Skaro AI, Leventhal JR, et al. Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus[J]. Clin J Am Soc Nephrol, 2012, 7(3):504-512. doi: 10.2215/CJN.06940711 [19] Morozumi K, Takeda A, Otsuka Y, et al. Recurrent glomerular disease after kidney transplantation: an update of selected areas and the impact of protocol biopsy[J]. Nephrology, 2014, 19(Suppl 3):6-10. http://www.bioportfolio.com/resources/pmarticle/1007371/Recurrent-glomerular-disease-after-kidney-transplantation-An-update-of-selected-areas-and.html [20] Koshino K, Ushigome H, Sakai K, et al. Outcome of tonsillectomy for recurrent IgA nephropathy after kidney transplantation[J]. Clin Transplant, 2013, 27(Suppl 26):22-28. http://www.medscape.com/medline/abstract/24299232 [21] Berthelot L, Robert T, Vuiblet V, et al. Recurrent IgA nephropathy is predicted by altered glycosylated IgA, autoantibodies and soluble CD89 complexes[J]. Kidney Int, 2015, 88(4):815-822. doi: 10.1038/ki.2015.158 [22] Edström Halling S, Söderberg MP, Berg UB. Predictors of outcome in paediatric IgA nephropathy with regard to clinical and histopathological variables (Oxford classification)[J].Nephrol Dial Transplant, 2012, 27(2):715-722. doi: 10.1093/ndt/gfr339 [23] Magistroni R, D'Agati VD, Appel GB, et al. New developments in the genetics, pathogenesis, and therapy of IgA nephropathy[J]. Kidney Int, 2015, 88(5):974-989. doi: 10.1038/ki.2015.252 [24] Ji SM, Xie KN, Cheng DR, et al. Long-term outcome of kidney transplantation from deceased donors with early graft dysfunction: a single-center analysis[J]. Indian J Appl Res, 2015, 5(5):761-764. http://worldwidejournals.in/ojs/index.php/ijar/article/download/9537/9622 [25] Shima Y, Nakanishi K, Kamei K, et al. Disappearance of glomerular IgA deposits in childhood IgA nephropathy showing diffuse mesangial proliferation after 2 years of combination/prednisolone therapy[J]. Nephrol Dial Transplant, 2011, 26(1):163-169. doi: 10.1093/ndt/gfq387 [26] Sato K, Ishida H, Uchida K, et al. Risk factors for recurrence of immunoglobulin a nephropathy after renal transplantation: single center study[J]. Ther Apher Dial, 2013, 17(2):213-220. doi: 10.1111/tap.2013.17.issue-2 [27] Yuan Y, Wang Q, Ni Z, et al. Long-term kidney survival analyses in IgA nephropathy patients under steroids therapy: a case control study[J]. J Transl Med, 2015, 13:186. doi: 10.1186/s12967-015-0549-2 [28] Sofue T, Inui M, Hara T, et al. Association between post-transplantation immunoglobulin A deposition and reduced allograft function[J]. Transplant Proc, 2015, 47(2):332-336. doi: 10.1016/j.transproceed.2015.01.011 [29] Novak J, Rizk D, Takahashi K, et al. New insights into the pathogenesis of IgA nephropathy[J]. Kidney Dis, 2015, 1(1):8-18. doi: 10.1159/000382134 -
下载:
点击查看大图
图(3)
计量
- 文章访问数: 369
- HTML全文浏览量: 208
- PDF下载量: 24
- 被引次数: 0
